BeiGene
BGNE
$265.65
Share price
0.49%
Change (1 day)
23.20%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Total assets
Total assets on the balance sheet as of September 2024 : C$8.38 Billion
According to BeiGene 's latest financial reports the company's total assets are C$8.38 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
BeiGene - Total assets on balance sheet (from 2014 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-12-31 | C$7.69 B | -11.05% |
| 2022-12-31 | C$8.65 B | -20.42% |
| 2021-12-31 | C$10.87 B | 52.32% |
| 2020-12-31 | C$7.14 B | 239.14% |
| 2019-12-31 | C$2.10 B | -31.29% |
| 2018-12-31 | C$3.06 B | 132.92% |
| 2017-12-31 | C$1.31 B | 141.25% |
| 2016-12-31 | C$0.54 B | 236.69% |
| 2015-12-31 | C$0.16 B | 160.3% |
| 2014-12-31 | C$62.22 M | 395.47% |
| 2013-12-31 | C$12.55 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 | C$26.13 M | -99.69% | 🇺🇸 USA |
 | C$3.16 B | -62.27% | 🇺🇸 USA |